Stockholders Equity (Tables)
|
3 Months Ended |
Mar. 31, 2024 |
|---|
| Stockholders Equity [Abstract] |
|
| Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders |
As of March 31, 2024, the Company
had the following outstanding warrants to purchase Common Stock issued to stockholders:
| Warrant |
|
Issuance Date |
|
Expiration
Date |
|
Exercise
Price
Per Share |
|
|
Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Public Warrants |
|
IPO (December 13, 2018) |
|
October 28, 2024 |
|
|
11.50 |
|
|
|
3,500,000 |
|
| 2021 Registered Direct Offering Warrants |
|
SPA (July 28, 2021) |
|
January 28, 2027 |
|
|
5.00 |
|
|
|
2,812,501 |
|
| Pre-Funded Warrants |
|
February 27, 2023 |
|
- |
|
|
0.001 |
|
|
|
1,869,755 |
|
| Pre-Funded Warrants |
|
May 4, 2023 |
|
- |
|
|
0.001 |
|
|
|
7,962,694 |
|
| Merger Warrants |
|
March 15, 2024 |
|
January 28, 2027 |
|
|
5.00 |
|
|
|
2,166,497 |
|
| Private Placement Warrants |
|
March 15, 2024 |
|
Two years after the stockholder approval |
|
|
0.2311 |
|
|
|
108,208,500 |
|
| Agents Warrants |
|
March 15, 2024 |
|
Two years after the stockholder approval |
|
|
0.2311 |
|
|
|
9,523,809 |
|
| |
|
|
|
|
|
|
|
|
|
|
136,043,756 |
|
|
| Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model |
| |
|
Three Months Ended
March 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Underlying value of Common Stock ($) |
|
|
0.23 |
|
|
|
- |
|
| Exercise price ($) |
|
|
0.23 |
|
|
|
- |
|
| Expected volatility (%) |
|
|
100.6 |
|
|
|
- |
|
| Expected terms (years) |
|
|
2.32 |
|
|
|
- |
|
| Risk-free interest rate (%) |
|
|
4.4 |
|
|
|
- |
|
|
| Schedule of Options Granted to Purchase |
A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:
| |
|
For the Three Months Ended
March 31, 2024 |
|
| |
|
Number of
Options |
|
|
Weighted
Average
Exercise Price |
|
|
Aggregate
Intrinsic
Value |
|
| Outstanding at the beginning of period |
|
|
5,280,711 |
|
|
$ |
0.54 |
|
|
$ |
72 |
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Forfeited |
|
|
(87,363 |
) |
|
$ |
0.37 |
|
|
|
|
|
| Expired |
|
|
- |
|
|
|
- |
|
|
|
|
|
| Exercised |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Outstanding at the end of period |
|
|
5,193,348 |
|
|
|
0.54 |
|
|
$ |
587 |
|
| Exercisable at the end of period |
|
|
3,249,620 |
|
|
|
0.57 |
|
|
|
|
|
| Weighted average remaining contractual life of outstanding options – years as of March 31, 2024 |
|
|
6.42 |
|
|
|
|
|
|
|
|
|
|
| Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock |
As of March 31, 2024, the Company
had the following outstanding compensation related warrants to purchase Common Stock:
| Warrant |
|
Issuance
Date |
|
Expiration
Date |
|
Exercise
Price
Per Share |
|
|
Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to scientific founders |
|
November 27, 2017 |
|
|
|
|
- |
|
|
|
2,974 |
|
| Landlord Warrants* |
|
March 15, 2024 |
|
January 28, 2027 |
|
|
5.00 |
|
|
|
250,000 |
|
| |
|
|
|
|
|
|
|
|
|
|
252,974 |
|
|
| Schedule of Stock-Based Payment Expenses |
The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
| |
|
Three Months Ended
March 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Research and development expenses, net |
|
|
65 |
|
|
|
87 |
|
| General and administrative |
|
|
112 |
|
|
|
88 |
|
| |
|
|
177 |
|
|
|
175 |
|
|